Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares

Reuters
2025.11.26 01:31
portai
I'm PortAI, I can summarize articles.

Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, has reported the sale of common shares, as per an SEC filing. This event is significant for the company and its stakeholders.

Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-297855), on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer